The company is growing year-over-year case volumes while taking market share, though revenue dollars declined due to product and price mix shifts. In 2026, Treace plans to commercialize Lapiplasty Lightning, a next-generation platform designed to reduce surgical steps and support greater accuracy of 3D bunion correction. Management expects full-year 2026 revenue of $202–$212 million with approximately 50% reduction in cash usage versus 2025.
Cyborg Score Rationale
Despite beating analyst expectations, Q1 2026 revenue declined 10% year-over-year while net losses widened. 2026 guidance implies flat-to-6% revenue decline versus 2025 with adjusted EBITDA losses expected to remain around $6 million. The company shows improving operational efficiency but faces top-line pressure and persistent losses.
Top Insights
Year-over-year case volume growth suggests underlying demand strength despite revenue declines driven by product and price mix dynamics.
Lapiplasty Lightning commercialization in 2026 aims to reduce surgical complexity and improve procedural accuracy, key differentiators in bunion surgery.
Company has $51.9 million cash on hand plus $115 million credit facility access, providing runway for product launches and profitability initiatives.
Chief Commercial Officer departed in April 2026; responsibilities absorbed by existing leadership reporting directly to CEO, signaling organizational restructuring.
Named Competitors
Zimmer Biomet Bunion Solutions — Established orthopedic bunion surgical solutions
Stryker Orthopedic — Broad musculoskeletal portfolio including bunion repair
Smith & Nephew Orthopedic — Diversified orthopedic devices and bunion solutions
Recent Developments
(May 2026) Q1 2026 revenue $47.2M, down 10% YoY; net loss widened to $18.0M
(April 2026) Chief Commercial Officer departure; CCO role eliminated with responsibilities distributed to existing staff
(2026) Planned commercialization of Lapiplasty Lightning next-generation platform with enhanced instrumentation and SpeedPlate dynamic fixation
(May 2026) Reaffirmed full-year 2026 revenue guidance of $202M–$212M with expected 50% reduction in cash usage
Open the full interactive Treace Medical Concepts, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.